The UK and US have agreed to a major commercial pact that will keep no import taxes on British drug shipments being sold in the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to boost funding on medicines through the NHS. This move secures that import taxes on these key products will stay at nothing for a period of the next three years.
This agreement comes after previous warnings to significantly raise duties on branded drug imports, with potential rates discussed reaching one hundred percent.
"This agreement between the Britain reinforces the global environment for innovative medicines and brings much-needed balance to transatlantic pharmaceutical trade," an announcement noted.
Economic Importance
Drugs represent one of the UK's biggest goods shipped to the America, which is clearly the largest market for large British pharmaceutical firms.
Export figures indicate that in the 12 months leading up to September, the UK exported medicines valued at billions to the US. This figure made up a significant portion of British export trade in that period.
"This deal protects jobs, stimulates investment and sets the stage for the UK to become a international leader for biotech and pharma," the Business and Trade Secretary commented.
Detailed NHS Changes
The deal includes several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new medicines to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a target to increase total NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the next decade.
- Payback Limit: The amount manufacturers must refund to the NHS to stay within budget will be capped at fifteen percent. Previously, repayments topped 20%.
Recent Tensions
The deal takes place against a protracted dispute between the drug companies and the ministers over medicine costs and regulatory access.
The disagreement were exacerbated by claims that US customers were charged several times more for the identical medicines than patients in the UK and Europe.
Recently, several large drug company projects in the UK have been halted or scrapped, while major investments have been directed toward American operations.
One official stated that the NHS had to spend more on medicines, noting that its spending on drugs had shrunk as a percentage of its resources over the past decade.
